Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Trials & Approvals

Updates on new clinical tirals being performed in China, trial updates and drug approvals...

Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer

Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid

CanSino One-Shot COVID Vaccine Accepted by WHO

Belief BioMed Reports Positive Data for Hemophilia Gene Therapy

Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022